Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. News
  7. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Vifor Pharma Confirms Talks with Market Participants Amid Reported CSL Interest; Shares Surge 21%

12/02/2021 | 10:44pm EST


© MT Newswires 2021
All news about VIFOR PHARMA AG
07:32aVFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculiti..
BU
01/18VIFOR PHARMA : Fairness Opinion Vifor Pharma
PU
01/18CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held ..
BU
2021Vifor Pharma's Veltassa Cuts Serum Potassium Levels in Heart Failure Patients in Late-S..
MT
2021Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
BU
2021Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®
CI
2021Cara Therapeutics' Korsuva Injection Receives TDAPA Reimbursement
MT
2021Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
BU
2021Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing ..
CI
2021Vifor Pharma to Sell Finished Drug Product Manufacturing Business to CordenPharma
MT
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Financials
Sales 2021 1 821 M 1 991 M 1 991 M
Net income 2021 265 M 289 M 289 M
Net cash 2021 395 M 432 M 432 M
P/E ratio 2021 42,7x
Yield 2021 1,34%
Capitalization 10 507 M 11 478 M 11 483 M
EV / Sales 2021 5,55x
EV / Sales 2022 4,91x
Nbr of Employees 2 384
Free-Float 72,2%
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 162,00 CHF
Average target price 152,00 CHF
Spread / Average Target -6,17%
EPS Revisions
Managers and Directors
Shah Abbas Hussain Chief Executive Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Michel Burnier Independent Director
Romeo Cerutti Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
VIFOR PHARMA AG-0.22%11 454
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992